Cervantes A
Cervantes A
Professor of Medicine. University of Valencia
Verified email at uv.es
Cited by
Cited by
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont, A Figer, M Seymour, M Homerin, A Hmissi, J Cassidy, ...
Journal of Clinical Oncology 18 (16), 2938-2947, 2000
A phase 3 trial of bevacizumab in ovarian cancer
TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ...
New England Journal of Medicine 365 (26), 2484-2496, 2011
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ...
Annals of Oncology 27 (8), 1386-1422, 2016
Capecitabine as adjuvant treatment for stage III colon cancer
C Twelves, A Wong, MP Nowacki, M Abt, H Burris III, A Carrato, J Cassidy, ...
New England Journal of Medicine 352 (26), 2696-2704, 2005
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making
HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ...
Annals of oncology 23 (10), 2479-2516, 2012
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with …
M Peeters, T Jay Price
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study
C Tournigand, A Cervantes, A Figer, G Lledo, M Flesch, M Buyse, ...
Journal of clinical oncology 24 (3), 394-400, 2006
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E Van Cutsem, A Cervantes, B Nordlinger, D Arnold
Annals of oncology 25 (suppl_3), iii1-iii9, 2014
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
R Labianca, B Nordlinger, GD Beretta, S Mosconi, M Mandalà, ...
Annals of oncology 24 (suppl_6), vi64-vi72, 2013
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
EC Smyth, M Verheij, W Allum, D Cunningham, A Cervantes, D Arnold
Annals of oncology 27 (suppl_5), v38-v49, 2016
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement
J Tabernero, GI Shapiro, PM LoRusso, A Cervantes, GK Schwartz, ...
Cancer discovery 3 (4), 406-417, 2013
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Glimelius, E Tiret, A Cervantes, D Arnold
Ann Oncol 24 (Suppl 6), 2013
Gastric cancer: epidemiology, pathology and treatment
SR Alberts, A Cervantes, CJH Van de Velde
Annals of oncology 14, ii31-ii36, 2003
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
R Glynne-Jones, L Wyrwicz, E Tiret, G Brown, C Rödel, A Cervantes, ...
Annals of Oncology 28, iv22-iv40, 2017
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head …
R Hitt, A López-Pousa, J Martínez-Trufero, V Escrig, J Carles, A Rizo, ...
J Clin Oncol 23 (34), 8636-8645, 2005
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ...
The Lancet Oncology 16 (8), 928-936, 2015
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG …
A Du Bois, M Quinn, T Thigpen, J Vermorken, E Avall-Lundqvist, ...
Annals of oncology 16 (suppl_8), viii7-viii12, 2005
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
E Van Cutsem, B Nordlinger, A Cervantes, ...
Annals of oncology 21 (suppl_5), v93-v97, 2010
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
GJS Rustin, I Vergote, E Eisenhauer, E Pujade-Lauraine, M Quinn, ...
International Journal of Gynecologic Cancer 21 (2), 2011
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed …
D Arnold, B Lueza, JY Douillard, M Peeters, HJ Lenz, A Venook, ...
Annals of oncology 28 (8), 1713-1729, 2017
The system can't perform the operation now. Try again later.
Articles 1–20